Eureka Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013399)
◆英語タイトル:Eureka Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013399
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Eureka Therapeutics Inc (Eureka Therapeutics) which focuses on the development of novel T cell immunotherapies for the treatment of solid tumors. Its pipeline encompasses drug candidates for various indications such as liver cancer, hematological cancer, lung cancer, head and cervical cancers, prostate cancer, multiple mylenoma, ovarian and peritoneal cancer, among others. Eureka Therapeutics utilizes its proprietary science platform which enables the discovery of fully-human antibodies against intracellular antigens via the MHC-peptide complex. The company works in academic collaboration with Memorial Sloan-Kettering Cancer Center for the joint discovery and research of new antibodies. Eureka Therapeutics is headquartered in Emeryville, California, the US.

Eureka Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Eureka Therapeutics Raises USD26.6 Million in Venture Funding 10
Eureka Therapeutics to Raise USD40 Million in Venture Financing 11
Eureka Therapeutics Raises USD21 Million in Series C Venture Financing 12
Partnerships 13
Zhongyuan Union Cell & Gene Engineering to Form Joint Venture with Tibet Based Biotechnology Firm and Eureka Therapeutics 13
Janssen Biotech Enters into Agreement with Eureka Therapeutics 14
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 15
Licensing Agreements 16
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 16
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 17
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 18
Eureka Therapeutics Inc – Key Competitors 20
Eureka Therapeutics Inc – Key Employees 21
Eureka Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
Apr 20, 2017: Eureka Therapeutics Expands Scientific Advisory Board with Appointment of Industry Leaders Dr. Hideho Okada and Dr. Nai-Kong Cheung 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eureka Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Eureka Therapeutics Raises USD26.6 Million in Venture Funding 10
Eureka Therapeutics to Raise USD40 Million in Venture Financing 11
Eureka Therapeutics Raises USD21 Million in Series C Venture Financing 12
Zhongyuan Union Cell & Gene Engineering to Form Joint Venture with Tibet Based Biotechnology Firm and Eureka Therapeutics 13
Janssen Biotech Enters into Agreement with Eureka Therapeutics 14
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 15
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 16
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 17
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 18
Eureka Therapeutics Inc, Key Competitors 20
Eureka Therapeutics Inc, Key Employees 21

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Eureka Therapeutics Inc-製薬・医療分野:企業M&A・提携分析(Eureka Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆